Why is Transgene Biotek falling/rising?

As of 18-Sep, Transgene Biotek Ltd is experiencing a decline in its stock price, currently at 3.95, which reflects a decrease of 0.43 or 9.82%. The stock has underperformed its sector by 9.71% today and has fallen after four consecutive days of gains. It is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Over the past month, the stock has decreased by 10.84%, and year-to-date, it has seen a significant drop of 42.17%. While there has been a slight increase in investor participation, with a delivery volume rise of 1.09% against the 5-day average, the overall sentiment remains negative, contributing to the stock's recent downward movement. There is no information available regarding positive or negative factors that could influence the stock.
In the broader market context, Transgene Biotek's short-term performance over the past week shows a gain of 4.50%, which is notably higher than the Sensex's increase of 1.80%. However, this positive short-term return is overshadowed by the stock's longer-term performance, where it has underperformed significantly compared to the benchmark, particularly over the past month and year. The stark contrast in returns indicates that while there may have been some recent interest in the stock, the overall trend remains bearish, reflecting broader challenges faced by the company compared to the market.